![]() ADC Therapeutics ADC Therapeutics is a biotechnology company that develops drug conjugates for the treatment of both solid and haematological cancers. | ![]() Immunomedics Immunomedics is a developer of monoclonal antibody-based products for the targeted treatment of cancer. | ![]() Ablynx Ablynx is a biopharmaceutical company engaged in the development of Nanobodies, proprietary therapeutic proteins based on single-domain antibody fragments. | |
Founding Date | Founding Date 2010 | Founding Date 1982 | Founding Date 2001 |
Type | Type Public | Type Subsidiary | Type Subsidiary |
Tags | |||
Locations | Locations Epalinges, CH HQ London, GB New Providence, US | Locations Morris Plains, US HQ | Locations Gent, BE HQ |
Employees | Employees 1162% increase | Employees 8914% decrease | Employees 1252% decrease |
Financial | |||
Revenue (est.) | Revenue (est.) $81.4m (FY, 2025) | Revenue (est.) $295k (FY, 2019) | Revenue (est.) €85.2m (FY, 2016) |
Cost of goods | Cost of goods $5.1m (FY, 2025) | Cost of goods N/A | Cost of goods N/A |
Gross profit | Gross profit $76.3m (FY, 2025) | Gross profit $295k (FY, 2019) | Gross profit N/A |
Net income | Net income ($142.6m) (FY, 2025) | Net income ($357.3m) (FY, 2019) | Net income (€1.1m) (FY, 2016) |
Operating ⚠ | |||
Patents (US) | Patents (US) N/A | Patents (US) 405 (Sep, 2022) | Patents (US) 50 (Q2, 2017) |
Funding | |||
Total funding raised | Total funding raised $ 526m | Total funding raised $ 30m | Total funding raised $ 498.8m |

Immunomedics is a developer of monoclonal antibody-based products for the targeted treatment of cancer.
View company
Ablynx is a biopharmaceutical company engaged in the development of Nanobodies, proprietary therapeutic proteins based on single-domain antibody fragments.
View company